You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Large cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Active, not recruiting
  • ALK-Positive Anaplastic Large Cell Lymphoma
  • RNAseq
  • Toulouse, France
    IUCT-Oncopole University Hospital
Jul 3, 2023

Communication Training Intervention for Large B-Cell Lymphoma

Recruiting
  • Lymphoma, B-Cell
  • +5 more
  • Hematolo-GIST Training
  • Participants Appointment
  • New York, New York
  • +2 more
Jul 3, 2023

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma Trial in United States

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +14 more
  • Cholecalciferol
  • Laboratory Biomarker Analysis
  • Scottsdale, Arizona
  • +4 more
Jan 16, 2023

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)

Completed
  • Anaplastic Large Cell Lymphoma
  • Vinorelbine
  • Shanghai, Shanghai, China
    Shanghai Children's Medical Center
Jul 23, 2022

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma Trial in Seoul

Completed
  • Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
    • Seoul, Gangnam-Gu, Korea, Republic of
      Samsung Medical Center
    Feb 4, 2022

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023

    Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
    • (no location specified)
    Sep 5, 2023

    Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

    Recruiting
    • Anaplastic Large Cell Lymphoma, ALK-Positive
    • +2 more
    • Paris, France
    • +1 more
    Sep 27, 2022

    Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

    Not yet recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • +3 more
    • Relmacabtagene Autoleucel
    • +2 more
    • Guangzhou, Guangdong, China
    • +12 more
    Oct 24, 2023

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

    Active, not recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • BEBT-908 for injection
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Oct 8, 2023

    Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +23 more
    • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jan 4, 2023

    DLBCL Trial (Polatuzumab Vedotin)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • Polatuzumab Vedotin
    • (no location specified)
    Jul 12, 2023

    Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

    Not yet recruiting
    • Large B-cell Lymphoma
    • (no location specified)
    Oct 3, 2023

    Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma

    Recruiting
    • Anaplastic Large Cell Lymphoma
    • +19 more
    • Duarte, California
    • +2 more
    Aug 15, 2022

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib, Polatuzumab vedotin and Rituximab
    • Shanghai, Shanghai, China
      Zhongshan Hospital，Fudan University
    Jul 10, 2023

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib, Polatuzumab Vedotin, Rituximab
    • Shanghai, Shanghai, China
      Zhongshan Hospital，Fudan University
    Jul 10, 2023